Virax Biolabs Group Ltd VRAX

$1.22 -0.02 (-1.21%)

Valuation

Market cap
972,000
Revenue TTM
$10,000
Net income TTM
$-5,020,000
PE ratio
0.00
Forward PE
—
Profit margin
-50,200.00%
Debt to equity
0.00

Trading

Volume
33,900
Avg volume
478,884
Day's range
$1.20 – $1.27
Shares out
797,000
Stochastic %K
10%
Beta
1.40
Analysts
Sell
Price target
$25.00

Price

Company profile

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic e...

Show more

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Phone
44 20 7788 7414
Website
https://viraxbiolabs.com
Address
BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, United Kingdom

Latest news

Stocktwits

8Kobe24 Oct 23, 5:03 PM
$VRAX It just did a Reverse Split! I'm sure a buyback would definitely be a great idea and that management can easily be reached and talked to about it...doesn't sound desperate at all or sound like it's coming from someone who posted, and the stock is down ~30% from that post. seems legit to me
0 replies
SDBiotechInvestor Oct 23, 4:09 PM
$VRAX FYI - I made a very strong argument to implement a stock buyback given the incredible valuation gap and the favorable runway. I was told CEO + BOD are going to contemplate it and if they agree with the logic there will be a PR forthcoming. I think this is the best past fwd to stop the low vol manipulation. If they do indeed implement a $1,000,000 share buyback I could see this 5x from here.
2 replies
SDBiotechInvestor Oct 22, 5:48 PM
$VRAX Officially trading 75% below cash and 83% below total assets. Spoke with the company and they understand the low volume manipulation. Beyond execution on commercial and PAIS front I gave a few suggestions.
2 replies
TraderBuckNKY Oct 21, 5:11 PM
$VRAX SEC Filing today...
1 replies
TraderBuckNKY Oct 17, 1:14 AM
$VRAX good info for all current and potential investors....: https://d1io3yog0oux5.cloudfront.net/_5746a1188721e0a3942ed2934668a44d/viraxbiolabs/db/2309/21669/pdf/Virax_Biolabs_Investor_Deck_Q3.pdf
0 replies
SDBiotechInvestor Oct 15, 4:11 PM
$VRAX Cash + Current Assets = $7/share. Any kind of meaningful news here can send this to the moon. I'm in very heavy. Matter of patience on this as they are overdue on PAIS news.
2 replies
Kculligan15 Oct 15, 3:48 PM
$VRAX let’s go! This is highly underpriced
1 replies
SDBiotechInvestor Oct 13, 3:51 PM
$VRAX Should get some news on their PAIS development soon. May update sent this up 400%.
0 replies